Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


The next big thing for global Pharma

Oct 15, 2009

Today's article highlights the important role that branded generics are expected to play in the global pharmaceutical market and how Indian pharma will benefit from the same

Cadila: Racing ahead

Jul 9, 2002

A 16% rise in turnover reported by Cadila for FY02 is quite encouraging, especially considering the fact that the first half yearly growth was a mere 7%. On an annual basis, operating margins have also shown an improvement. The company has ambitious plans to emerge amongst the top 3 pharmaceutical companies in India by March 2004. Post the acquisition of controlling stake in German Remedies, the company is open to further in-organic growth.

Unichem: Strong growth

Jun 20, 2002

A wider therapeutic reach, increasing presence in exports and restructuring benefits have helped Unichem Labs display robust numbers for FY02. The company's margins have shown steady improvement in the last two years due to product introductions in high growth segments. The company ended FY02 with a 55% growth in net profits.

Kopran: Lacks future clarity

Jan 3, 2002

Recently, Kopran sold its top selling Cardiovascular ‘Aten’ brand to Cadila for a consideration of Rs 950 m. The company is also believed to be in talks with other pharmaceutical majors for the sale of its remaining formulation business. Kopran seems to trying to change the perception and business profile to that of a company focused purely on the OTC segment. So far the company has met with initial success with its brand ‘Smyle’.

Lupin Ltd: Emerging Strong

Dec 18, 2001

Last year, Lupin Chemicals and Lupin Laboratories merged to create a giant entity, Lupin Ltd., with sales turnover in excess of Rs 9 bn. The merger has helped the company in consolidating its leadership position in the anti –TB market. Further, the company is taking strides to become a recognized global player in the Cephalosporin (new generation anti-infectives) and is now considering research as a new thrust area.

Cadila: Aggressive growth strategy

Dec 11, 2001

The performance of Cadila Healthcare, so far in the current year has been modest. It has been able to log less than 7% growth in topline for the first half of the current year. However, the company is on an acquisition spree to log faster growth through in-organic route.

Nicholas: Are valuations attractive?

Nov 26, 2001

Nicholas strategy of growing through the inorganic route seems to be paying off well for the company. The recent Rs 2.4 bn acquisition of Rhone Poulenc is expected to catapult its turnover into top 5 pharma companies in India. Post merger with Rhone Poulenc, Nicholas growth numbers were quite stupendous.

Ciprofloxacin: Indian firms losing out

Oct 16, 2001

The Anthrax scare is spreading like fire in the US. Ciprofloxacin is the only antibiotic specifically approved by the FDA to treat anthrax infections, although other antibiotics are believed to be as effective. The demand for Ciprofloxacin has thus shot through the roof in the US. The US health administration has issued a directive to stock up Ciprofloxacin.

Mergers: The only survival route

Oct 12, 2001

Merger - It's the most talked about term today creating lot of excitement and speculative activity in the markets. With the turmoil in the equity markets, 'takeovers', 'open offers', 'buybacks' and 'acquisitions' are some of the terms, which are making the noise in the markets. But before Mergers & Acquisitions (M&A) activity speeds up, it has to actually pass through a long chain of procedures (both legal and financial), which at times delays the deal.

Unichem: Restructuring pays off

Sep 21, 2001

The restructuring exercise initiated by Unichem Laboratories seems to be bearing fruit. The company's margins have shown steady improvement in the last two years due to high margin product introductions and increasing focus on exports. The company's domestic formulations business grew by a robust 22.8% last fiscal.

Kopran: Uncertain Future

Sep 6, 2001

Kopran, promoted by Parijat Enterprise, is one of the integrated domestic pharmaceutical players. Its products Aten (cardiovascular), Vent (respiratory) and Smyle enjoy strong brand equity. The company is in the midst of business and financial restructuring. The company is trying to change the perception and business profile from that of a commodity bulk manufacturer and supplier to a formulations based company with an ability to create strong brands.

Cipla: Eyeing the biotech market

Sep 5, 2001

Cipla declared a 21% growth in revenues for the first five months ended August’01 at its AGM held on 4th September'01. Considering 1QFY02 figures, where revenues grew by 20% (gross), the first five months numbers reflect a better performance in two months viz July & August’01, especially when the industry as a whole is showing a decelerating growth. Few more details of the AGM as under.

Vaccines Market: An overview

Jun 7, 2001

The pharmaceutical market worldwide is shifting focus from curative to preventive healthcare and vaccines are playing an increasingly important role. Vaccines are basically antigenic preparation used to stimulate the production of antibodies and procure immunity from one or several diseases. Worldwide, pharmaceutical companies are concentrating on engineered vaccines of international standards with high purity, efficacy and tolerability with no major side effects with the help of biotechnology.

Cadila Healthcare: Take care

May 3, 2001

Cadila Healthcare Ltd. results are below our expectations. Though, year on year basis sales have grown by 6.5% (expected 10.5%), it has infact showed a negative growth (2.7%) on a sequential basis. Operating margins have dipped from 18% in Q3FY01 to a paltry 5.9% in Q4FY01. The sudden drop in operating margins is unexplained at this point of time. Thanks to substantial reduction in interest cost and income from parking of IPO funds, bottomline showed an apparent growth of 64%.

Cadila: poor man's Cipla

Oct 23, 2000

Cadila Healthcare has also made its mark in the domestic pharmaceutical market thanks to the reverse engineering. The company was formed after the spilt in the partnership between the Patel and Modi groups. (The latter own Cadila Pharmaceuticals).

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms